Trial intelligence / Profile preview

Prospective multicenter phase III study of Xeloda in biliary tract carcinoma

2007-003858-29Phase 3Active

Sponsor: University Hospital Tübingen
Start: Feb 2008
Modality: Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
Countries: 1

Overview

Phase 3 trial of capecitabine in gallbladder cancer and extrahepatic cholangiocarcinoma (eCCA), sponsored by University Hospital Tübingen. Primary endpoint: 2-year overall survival rate. Started Feb 2008; status: active.

Drugs

capecitabine

Conditions

gallbladder cancerextrahepatic cholangiocarcinoma (eCCA)

Beyond the preview

Go deeper on 2007-003858-29.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2007-003858-29.